A new tumor-modeling platform called a tumor-microenvironment-on-chip can be used to visualize and quantify how different types of cancer cells react differently to the chemotherapy drug doxorubicin
By creating a cell model of medulloblastoma from human cells rather than working with mouse cells, the researchers say they can be more confident that patients’ response to the drugs identified in the screenings may be more comparable to humans
"The bottom line is that so far there are only a few successful nanoparticle formulations approved and clinically used, so we need to start thinking out of the box."